Prostate cancer hormone therapy could harm men with heart conditions

Share this content:

Androgen-deprivation therapy (ADT) has been shown to improve overall survival for men with high-risk prostate cancer, but the treatment appears to carry a heightened risk of death for men with such disease as well as a history of heart failure (HF) or myocardial infarction (MI).

The project yielding this finding involved 14,594 men with cT1c-T3aN0M0 prostate cancer who were treated with brachytherapy-based radiation therapy at some point between 1991 and 2006. A total of 1,378 (9.4%) had a history of HF or MI.

Of the men with the heart conditions (median age 71.8 years), 22.6% underwent supplemental external beam radiation therapy, and 42.9% received neoadjuvant ADT for a median of 4 months.

Over a median follow-up period of 4.3 years, ADT was associated with a significantly increased risk of all-cause mortality, with 5-year estimates of 22.71% with the hormone therapy and 11.62% without.

“We found that for men with localized prostate cancer and a history of heart problems, treatment with hormones plus radiation was associated with a higher all-cause mortality than treatment with radiation alone, even for patients with high-risk malignant disease,” affirmed study lead author Paul L. Nguyen, MD, a radiation oncologist at the Dana-Farber/Brigham and Women's Cancer Center in Boston, Massachusetts, in a statement describing his group's findings, which were published online by the International Journal of Radiation Oncology*Biology*Physics. “Despite Phase 3 data supporting hormone therapy use for men with high-risk disease, the subgroup of men with a history of heart disease may be harmed by hormone therapy.”

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs